Establishment Labs, Puregraft enter distribution pact for autologous fat transfer products

Establishment Labs announced an agreement to distribute Puregraft’s line of autologous fat transfer products, according to a press release.

“Puregraft autologous fat transfer has demonstrated long term natural tissue retention, and will enable advanced cell and implant hybrid aesthetic and reconstructive treatments in combination with our innovative line of Motiva Implants,” José Chacón Quirós, CEO of Establishment Labs, a medical device company focused on next-generation breast implants, stated in the release. “We believe that incorporating the latest technologies into breast aesthetics, breast reconstruction and body contouring will improve patient outcomes significantly.”

The Puregraft autologous fat transfer allows plastic surgeons to achieve a more natural look and feel, using the patient’s own cells, when used in combination with the Motiva silicone breast implants, according to the release.

“We are delighted to work with Establishment Labs to advance the state of the art plastic surgery procedures,” Brad Conlan, CEO of Puregraft, stated in the release. “We … anticipate that hybrid procedures will become the new standard for breast augmentation, breast reconstruction and body contouring.”

The agreement includes an additional option to distribute Puregraft products in the United States and Canada, according to the release.

Reference: www.puregraft.com